Kimberly Long is Alchemab’s Vice President of Biology where she leads new target identification and validation. Prior to joining Alchemab Kimberly was Vice President of Biology at ROME Therapeutics and Casma Therapeutics. Prior to Casma Therapeutics, Kimberly held positions of increasing responsibility at Scholar Rock and Ironwood Pharmaceuticals. Kimberly eared a PhD in Biological Sciences from Stanford University and a BA in Biology from Northwestern University.